Table 3 Overall survival and time-to-treatment failure after treatment with eribulin

All

252

10.8 (8.5–13.1)

2.5 (2.1–2.8)

L-type

142

13.8 (10.1–22.3)

2.8 (2.3–3.7)

Non-L-type

110

6.5 (5.7–11.1)

2.2 (1.6–2.6)

Leiomyosarcoma

73

12.7 (8.5–20.6)

2.8 (2.1–3.7)

Liposarcoma

69

20.8 (8.9–not reached)

3.2 (1.7–5.5)

 Dedifferentiated

40

16.6 (8.8–not reached)

3.1 (1.7–5.7)

 Myxoid

12

27.6 (4.1–27.6)

5.0 (1.0–12.0)

 Well-differentiated

7

not reached (5.8–not reached)

9.9 (0.5–not reached)

 Pleomorphic

3

7.3 (6.9–8.5)

1.4 (1.4–2.0)

 Unknown

7

5.8 (1.8–not reached)

1.5 (0.5–5.8)

Undifferentiated pleomorphic sarcoma

19

8.1 (4.0–16.3)

2.3 (1.4–4.0)

Angiosarcoma

14

12.7 (3.4–16.9)

2.4 (0.7–5.5)

Synovial sarcoma

13

11.7 (4.5–16.0)

3.7 (2.3–4.6)

Rhabdomyosarcoma

12

4.5 (0.8–9.7)

1.2 (0.5–2.8)

Malignant peripheral nerve sheath tumor

6

3.3 (2.0–5.1)

1.5 (0.5–2.3)

Myxofibrosarcoma

5

11.1 (2.3–19.8)

8.1 (0.7–8.4)